{
    "paper_id": "5f59473f8d71381b06b2c19c1dad7e88a84b194f",
    "metadata": {
        "title": "",
        "authors": [
            {
                "first": "Matteo",
                "middle": [],
                "last": "Megna",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University of Naples Federico II",
                    "location": {
                        "country": "Italy"
                    }
                },
                "email": ""
            },
            {
                "first": "Maddalena",
                "middle": [],
                "last": "Napolitano",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University of Molise",
                    "location": {
                        "settlement": "Campobasso",
                        "country": "Italy"
                    }
                },
                "email": ""
            },
            {
                "first": "Gabriella",
                "middle": [],
                "last": "Fabbrocini",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University of Naples Federico II",
                    "location": {
                        "country": "Italy"
                    }
                },
                "email": ""
            }
        ]
    },
    "abstract": [],
    "body_text": [
        {
            "text": "Medical Hypotheses journal homepage: www.elsevier.com/locate/mehy",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Contents lists available at ScienceDirect"
        },
        {
            "text": "Dear Editor, SARS-Corona-Virus-2 related disease (COVID-19) which started in Wuhan, China on December 2019, is spreading rapidly throughout the world [1] . COVID-19 clinical spectrum is variable and may lead to respiratory failure, multiorgan and systemic manifestations [2] . COVID-19 patients showed lower leukocyte numbers, abnormal respiratory findings, and increased levels of plasma pro-inflammatory cytokines such as interleukin (IL)1-\u03b2, IL1RA, IL6, IL8, IL10 with Th1-Th17 cells appearing as the main source [3] . That is why recently tocilizumab, a monoclonal antibody blocking IL-6 action has been shown to be effective in COVID-19 subjects with cytokine storm risk [4] . Indeed, proinflammatory cytokine storms have been observed in critically COVID-19 patients which progress to multiple organ dysfunction and death [4, 5] . Therefore, cytokine storms early treatment and prevention is of crucial importance. In this context, the debate whether blocking other cytokines could reduce COVID-19 impact is growing [6] . Particularly, a cytokine that may be related to IL-6 in the context of viral infection is IL-17. Indeed, Hou et al. found in murine viral models that the excessive IL-6 level promotes the generation of Th17 cells, and the resulting IL-6 and IL-17 synergistically promote viral persistence by protecting virusinfected cells from apoptosis [7] . Another example is represented by influenza virus infection where high-mortality acute lung injury is associated with an increase in neutrophils in the airspace promoted by IL-17 [8] ; IL-17 receptor antagonist (RA) knockout mice recruited fewer neutrophils to the airway in response to influenza A virus with a decreased mortality and lower immune-related lung injury [8] . Targeting IL-17 in acute lung injury due to viral infection could be beneficial also because blocking IL-17 did not impair influenza virus clearance. Indeed, main Th17 cell effector cytokines were up-regulated in laboratory-confirmed A(H3N2) influenza infected humans supporting that increased amounts of IL-17 may be implicated in influenza pathogenesis and immune control, predicting disease severity [9] . A recent review showed that IL-17 functions are crucial in different settings of viral infections with its targeting being an effective alternative treatment to suppress viral infections and minimizing tissue pathology in several human diseases [10] . Finally, Huang et al. observed that IL-17 increased in intensive-care COVID-19 patients vs non intensive-care and controls with Zumla et al. hypothesizing that blocking IL-17 could have the potential to improve COVID-19\u2032s aberrant immune response and acute respiratory distress syndrome-related mortality [9] . Indeed, a Chinese clinical trial evaluating an anti-IL17 drug approved for psoriasis (ixekizumab) is already running [10] . Despite the effect of blocking IL-17 on Th2 response should be deeper investigated since SARS-CoV-2 also seems to stimulate Th-2 cytokines production (IL-4 and IL-10) that suppress Th1/Th17 mediated inflammation [3] , taken together all these data further underline the need of investigating on IL-17 blocking role in COVID19 which appears as a potential promising therapeutic target.",
            "cite_spans": [
                {
                    "start": 150,
                    "end": 153,
                    "text": "[1]",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 271,
                    "end": 274,
                    "text": "[2]",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 516,
                    "end": 519,
                    "text": "[3]",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 676,
                    "end": 679,
                    "text": "[4]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 828,
                    "end": 831,
                    "text": "[4,",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 832,
                    "end": 834,
                    "text": "5]",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 1022,
                    "end": 1025,
                    "text": "[6]",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 1366,
                    "end": 1369,
                    "text": "[7]",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 1551,
                    "end": 1554,
                    "text": "[8]",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 1741,
                    "end": 1744,
                    "text": "[8]",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 2150,
                    "end": 2153,
                    "text": "[9]",
                    "ref_id": "BIBREF8"
                },
                {
                    "start": 2401,
                    "end": 2405,
                    "text": "[10]",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 2713,
                    "end": 2716,
                    "text": "[9]",
                    "ref_id": "BIBREF8"
                },
                {
                    "start": 2836,
                    "end": 2840,
                    "text": "[10]",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 3055,
                    "end": 3058,
                    "text": "[3]",
                    "ref_id": "BIBREF2"
                }
            ],
            "ref_spans": [],
            "section": "May IL-17 have a role in COVID-19 infection?"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "The coronavirus 2019-nCoV epidemic: is hindsight 20/20?",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Malta",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "W"
                    ],
                    "last": "Rimoin",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "A"
                    ],
                    "last": "Strathdee",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "EClinicalMedicine",
            "volume": "20",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/j.eclinm.2020.100289"
                ]
            }
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19)",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Cascella",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Rajnik",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Cuomo",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "C"
                    ],
                    "last": "Dulebohn",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "PMID": [
                    "32150360"
                ]
            }
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Huang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Ren",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "395",
            "issn": "",
            "pages": "497--506",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Tocilizumab treatment in COVID-19: a single center experience",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Luo",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Qiu",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Med Virol",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1002/jmv.25801"
                ]
            }
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Dong",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "395",
            "issn": "",
            "pages": "507--520",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Should patients stop their biologic treatment during the COVID-19 pandemic",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "M"
                    ],
                    "last": "Bashyam",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "R"
                    ],
                    "last": "Feldman",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "J Dermatolog Treat",
            "volume": "2020",
            "issn": "",
            "pages": "1--2",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Interleukin-6 (IL-6) and IL-17 synergistically promote viral persistence by inhibiting cellular apoptosis and cytotoxic T cell function",
            "authors": [
                {
                    "first": "W",
                    "middle": [],
                    "last": "Hou",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "H"
                    ],
                    "last": "Jin",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "S"
                    ],
                    "last": "Kang",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "S"
                    ],
                    "last": "Kim",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "J Virol",
            "volume": "88",
            "issn": "15",
            "pages": "8479--89",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Critical role of IL-17RA in immunopathology of influenza infection",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "R"
                    ],
                    "last": "Crowe",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "A"
                    ],
                    "last": "Pociask",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "J Immunol",
            "volume": "183",
            "issn": "8",
            "pages": "5301--5311",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Th17 serum cytokines in relation to laboratory-confirmed respiratory viral infection: a pilot study",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Antalis",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "J Med Virol",
            "volume": "91",
            "issn": "",
            "pages": "963--71",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "The protective and pathogenic role of IL-17 in viral infection: friend or foe?",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Wen-Tao",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Open Biol",
            "volume": "210",
            "issn": "9",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {},
    "back_matter": [
        {
            "text": "All authors declare to not have conflict of interest as well as funding sources to declare.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Conflict of interest"
        }
    ]
}